Kodak (KODK) Q1 2026 earnings review
Operational Turnaround Eclipsed by Non-Operating Noise
Kodak delivered its third consecutive quarter of stable YoY revenue growth (+7%) and a massive 650% jump in Operational EBITDA to $15M, driven by strong pricing in the core Print segment. However, the GAAP bottom line tells a reversing story: net loss doubled to $16M. This optical deterioration is entirely due to the expected roll-off of non-cash pension income following the 2025 KRIP termination, combined with $9M in unexplained 'other charges.' While the multi-year deleveraging narrative is tracking perfectly—interest expense plummeted 57%—investors must monitor a sudden $38M inventory build that kept operating cash flows negative.
🐂 Bull Case
Gross profit surged 24% YoY to $57M, with margins expanding 300 basis points. Management is successfully passing on higher aluminum and manufacturing costs to customers.
The successful 2025 pension reversion strategy is paying dividends. Kodak applied $46M in KRIP redemption proceeds to pay down a required $50M term loan principal, decisively lowering future interest burdens.
🐻 Bear Case
Despite a $13M YoY increase in Operational EBITDA, operating cash flow remains negative (-$30M), heavily dragged down by a $38M sequential spike in inventory tied to commodity inputs.
A sudden $9M 'other charges' line item wiped out the majority of the operational EBITDA gains, pushing the company deeper into a GAAP net loss.
⚖️ Verdict: ⚪
Neutral. The core operations are structurally more profitable than a year ago, and the balance sheet is healing. However, cash burn tied to inventory and stagnant growth in the AM&C 'growth engine' prevent a fully bullish stance.
Key Themes
Print Segment Accelerating as the Unexpected Leader
Historically viewed as a legacy drag, the Print segment is now accelerating. Revenue grew 9% to $180M, and Operational EBITDA reversed from a $9M loss in 25Q1 to a $3M profit in 26Q1. The successful transition of the PROSPER 520 digital press into full production is validating management's investment in commercial print innovation.
AM&C Growth Engine Decelerating
The Advanced Materials & Chemicals (AM&C) segment—highly touted for its Pharma and EV battery initiatives—is decelerating. Revenue growth slowed to just 3% YoY (flat on a constant currency basis), and Operational EBITDA was completely flat at $7M. Investors need proof that the new cGMP pharmaceutical facility can generate meaningful scale.
Deleveraging Translates Directly to the Bottom Line
The mechanics of the KRIP pension reversion are yielding stable, structural improvements. Interest expense fell dramatically from $14M in 25Q1 to $6M in 26Q1. This $8M quarterly savings provides critical breathing room to fund ongoing operations and internal R&D without tapping external equity markets.
Optical Net Income Shock Explains the GAAP Miss
The GAAP net loss widening from $7M to $16M is misleading on an operational basis, but represents a real shift in P&L structure. In 25Q1, Kodak benefited from $22M in non-service pension income. Following the KRIP termination, this fell to just $4M in 26Q1. Without this non-cash padding, Kodak must rely purely on operating profit to achieve GAAP profitability.
Commodity Prices Forcing Reversing Cash Flows
Kodak burned $30M in operating cash flow this quarter. Management attributed a massive $38M increase in inventory to raw material costs for silver and aluminum. While the company successfully passed these costs on via pricing (evidenced by gross margin expansion), the physical cash required to hold this inventory is severely taxing their $299M cash balance.
Other KPIs
Accelerating significantly from $46 million in the prior year quarter. Gross margin hit 22%, proving that Kodak's 'smart revenue' strategy is overcoming inflationary pressures in manufacturing.
Decelerating from $337 million at year-end 2025. The $38 million reduction was driven by the $50 million debt principal repayment and $38 million inventory build, offset by $46 million in incoming pension reversion cash.
Key Questions
Transparency on Other Charges
The company reported $9 million in 'other charges, net' this quarter which deeply impacted the GAAP bottom line. What exactly comprises these charges, and are they recurring?
Inventory Management Strategy
Inventory jumped $38 million primarily due to silver and aluminum commodities. Is this an intentional forward-purchasing strategy to hedge against further inflation, or a mismatch in anticipated volume demand?
AM&C Pharma Revenue Ramp
With the cGMP pharmaceutical facility now FDA certified, when should investors expect to see the AM&C segment return to the double-digit revenue growth rates witnessed in mid-2025?
Capital Allocation Post-Deleveraging
With the term loan significantly reduced and the KRIP reversion finalized, what is the priority for the remaining $299 million in cash? Are aggressive stock buybacks on the table given the current equity valuation?